

BD Opens New \$38.6 Million Medication Management Manufacturing Facility in Tijuana

Facility Will Add 500 New Jobs Over the Next Two Years

TIJUANA, Baja California, Mexico (Nov. 30, 2022)– BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was joined by government officials from Mexico and Baja California to inaugurate a new \$38.6 million manufacturing facility in Tijuana that will produce devices and technologies that help improve medication safety within health care settings.

The new 15,775-square-meter facility is expected to add 500 new jobs over the next two years. Phase I of the facility will create 75 jobs that will be responsible for manufacturing automated dispensing cabinets that health care professionals use to dispense medications to patients. The devices will be exported to countries in North America, Europe, Africa and Asia.

“Our new facility in Tijuana is BD’s 12th manufacturing plant in Mexico and is a testament to our commitment to Mexico and the strong relationship we’ve built in communities across the country over the past 65 years,” said Julio Duclos, Vice President and General Director of Mexico, the Caribbean and Central America for BD. “The 17,000 BD employees in Mexico are focused on producing high-quality medical devices that are used by health care providers and patients around the world. We look forward to continuing to grow in Mexico.”

The expansion of the infrastructure in Tijuana is part of a four-year strategic plan in which the company will invest \$1.2 billion (USD) to expand and upgrade its technology and production capacity in various regions of the world, including Mexico.

“BD has been a leader in leveraging the cross-border efficiencies that are created in the Tijuana-San Diego region, and this new plant will continue to help BD simplify our operations by combining a manufacturing site, a distribution center and the means to deliver products to the end customer in one place,” explained Puneet Sarin, President of Medication Management Solutions for BD. “By simplifying our operations, BD can continue to focus on advancing the world of health by developing new technologies that improve how medications are stored, dispensed and administered to help ensure optimal outcomes.”

Steps will be taken to obtain the certifications ISO 14001:2015 Environmental Management and Risk, Safe Company, ISO 45001 Occupational Health and Safety Management Systems, Clean Industry, Smoke-Free Company C-TPAT, BSI ISO 13485, MDSAP, CSA and Intertek.

For his part, the Secretary of Economy and Innovation, C.P. Kurt Honold Morales, indicated that “there is a positive perspective, since we see that companies established in Baja California, such as BD, are expanding with new lines of business and considering integrating regional suppliers. We reiterate respect for the rule of law for an environment confidence that encourages investment.”

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit [bd.com](https://www.bd.com) or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter [@BDandCo](https://twitter.com/BDandCo).

Contacts:

Media:

Investors:

Troy Kirkpatrick
VP, Public Relations
858.617.2361
troy.kirkpatrick@bd.com

Francesca DeMartino
SVP, Head of Investor Relations
201.847.5743
francesca.demartino@bd.com

<https://news.bd.com/2022-11-30-BD-Opens-New-38-6-Million-Medication-Management-Manufacturing-Facility-in-Tijuana>